While data-rich submissions are essential for Health Technology Assessment (HTA) bodies, a brief, articulate in-person testimony from a patient can have a disproportionately large impact. This "living human perspective" often carries more emotional weight and creates a more memorable impression than pages of text data.
Related Insights
To combat the high drop-off rate of potential bone marrow donors, a simple video message from the patient awaiting the transplant could be transformative. This humanizes the abstract request, turning a stranger into a real person—a mother, child, or sibling—making the decision far more compelling than an anonymous call.
A patient's self-reported data can be incomplete or biased, as they may only report the "good measures." To get the full picture, companies must gather input from multiple sources, like caregivers and clinicians. Each perspective helps correct the others, creating a more accurate and holistic view of the patient's journey.
Don't wait until Phase 3 to think about commercialization. Biotech firms must embed secondary endpoints in Phase 2 trials that capture quality of life and patient journey insights. This data is critical for building a compelling value proposition that resonates with payers and secures market access.
The pharmaceutical industry is often misunderstood because it communicates through faceless corporate entities. It could learn from tech's "go direct" strategy, where leaders tell compelling stories. Highlighting the scientists and patient journeys behind breakthroughs could dramatically improve public perception and appreciation.
Text descriptions of physical pain are often vague. To improve an AI coach's helpfulness, use multi-modal inputs. Uploading a photo and circling the exact point of pain or a video showing limited range of motion provides far more precise context than words alone.
To be effective, the patient's lived experience cannot remain a "soft narrative." It must be converted into hard data points—like reduced healthcare utilization for payers or influence on treatment pathways for clinicians—to become a decision-making tool they cannot ignore.
A crucial piece of advice for biotech founders is to interact with patients as early as possible. This 'patient first' approach helps uncover unmet needs in their treatment journey, providing a more powerful and differentiated perspective than focusing solely on the scientific or commercial landscape.
Despite the telehealth boom, 95% of ZocDoc's appointments for physical medicine are booked for in-person visits. The data suggests that while patients value the *option* of telehealth, they don't actually want it for somatic care, where a physical examination is crucial. The primary use case remains remote mental health services.
The company's clinical trials go beyond standard pain scores to track improvements in function, sleep, and patient satisfaction. Demonstrating that patients can climb stairs, drive, and sleep better provides a more compelling value proposition for a faster return to normal life, resonating with patients, surgeons, and payers alike.
Instead of generic praise like "we love this product," use testimonials with specific numbers (e.g., "saved 12 hours a month"). This allows prospects to visualize tangible value and see themselves in the outcome, making social proof significantly more persuasive.
